Abbott director granted stock units and options
ABBOTT LABORATORIES director Michael O’Grady reported equity awards under the company’s 2026 Incentive Stock Program.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ABBOTT LABORATORIES director Michael O’Grady reported equity awards under the company’s 2026 Incentive Stock Program. He was granted 2,286 restricted stock units, each convertible into one Abbott common share upon separation from service, death, or a change in control as defined in the program.
He also received an option to buy 5,929 Abbott common shares at an exercise price of $91.86 per share, expiring on April 23, 2036, in a transaction exempt from Section 16 under Rule 16b-3. Following these awards, his direct holdings of Abbott common shares reported in this filing total 7,603 shares.
Insider Trade Summary
Grant/Award: 8,215 shares
Grant/Award
2 txns
Insider
O'Grady Michael
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (right to buy) | 5,929 | $0.00 | $0.00 |
| Grant/Award | Common shares without par value | 2,286 | $0.00 | $0.00 |
Holdings After Transaction:
Option (right to buy) — 5,929 contracts (Direct);
Common shares without par value — 7,603 shares (Direct)
Footnotes (2)
- F1. Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
- F2. Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3.
Key Figures
Restricted stock units granted: 2,286 units
Stock options granted: 5,929 options
Option exercise price: $91.86 per share
+3 more
6 metrics
Restricted stock units granted
2,286 units
Award under Abbott Laboratories 2026 Incentive Stock Program
Stock options granted
5,929 options
Option (right to buy) Abbott common shares
Option exercise price
$91.86 per share
Conversion or exercise price for 5,929-share option grant
Option expiration date
April 23, 2036
Expiration for stock option granted on April 24, 2026
Shares held after transaction
7,603 shares
Total Abbott common shares directly held after awards
Section 16 exemption
Rule 16b-3
Stock option grant exempt from Section 16 under Rule 16b-3
Key Terms
Restricted stock unit, Incentive Stock Program, change in control, Section 16, +1 more
5 terms
Restricted stock unit financial
"Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Incentive Stock Program financial
"granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program")"
change in control financial
"on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Section 16 regulatory
"Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
Rule 16b-3 regulatory
"Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Abbott Laboratories (ABT) director Michael O’Grady receive in this Form 4 filing?
Michael O’Grady received equity awards, not open-market trades. He was granted 2,286 restricted stock units and an option for 5,929 Abbott common shares under the 2026 Incentive Stock Program, reflecting routine director compensation rather than discretionary buying or selling.
How many restricted stock units did Michael O’Grady receive from Abbott Laboratories (ABT)?
Michael O’Grady was granted 2,286 restricted stock units. Each unit represents the right to receive one Abbott common share, payable on the earlier of his separation from service, death, or a qualifying change in control, as defined in Abbott’s 2026 Incentive Stock Program.
What are the key terms of Michael O’Grady’s Abbott (ABT) stock option grant?
He received an option for 5,929 Abbott common shares with an exercise price of $91.86 per share. The option was granted under Abbott’s 2026 Incentive Stock Program and expires on April 23, 2036, in a transaction exempt from Section 16 under Rule 16b-3.
When will Michael O’Grady’s Abbott (ABT) restricted stock units be paid out?
The 2,286 restricted stock units will be paid on a one-to-one basis in common shares on the earlier of O’Grady’s separation from service, his death, or a change in control, according to the terms of Abbott’s 2026 Incentive Stock Program.
Were Michael O’Grady’s Abbott (ABT) equity awards open-market purchases or sales?
The transactions are grants under a company plan, not market trades. Both the restricted stock units and stock option were awarded under Abbott’s 2026 Incentive Stock Program and are classified as grant or award acquisitions exempt from Section 16 under Rule 16b-3.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates